Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 18/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811279 | 0.99 | PDE2A (0.44) | PDE2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL6994533 | 0.92 | PDE2A (0.40) | PDE2A | |
| SCHEMBL6990130 | 0.92 | PDE2A (0.43) | PDE2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL6999255 | 0.91 | PDE2A (0.41) | PDE2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL7001331 | 0.90 | PDE2A (0.39) | PDE2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL6993982 | 0.90 | PDE2A (0.39) | PDE2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL6993988 | 0.90 | PDE2A (0.39) | PDE2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL4820826 | 0.90 | PDE2A (0.40) | PDE2A | |
| SCHEMBL6992536 | 0.90 | PDE2A (0.41) | PDE2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL6992543 | 0.90 | PDE2A (0.41) | PDE2ASMN1; SMN2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | claimed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | TUBB3, TUBA1C, TUBB1 | PDE2A 3218/4885SMN1; SMN2 655/4885KDM4E 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.